EUVIMEDEUVIMED entdecken
Kohortenstudie

HDL anti-inflammatory capacity and residual cardiovascular risk: A prospective cohort study

Congzhuo Jia, Wanying Wu, Xiayan Xu, Yun Xie, Yong Liu, Jiyan Chen

Journal of Clinical Lipidology · 2026-06 · 20 (6) · 1065-1077

DOI: 10.1016/j.jacl.2026.03.015 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Clinical Lipidology, 2026-06. Verfasst von Congzhuo Jia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzho…. Hauptthemen laut MEDLINE: Lipoproteins, HDL, Cardiovascular Diseases, Anti-Inflammatory Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Guangdong Provincial People's Hospital, National Natural Science Foundation of China, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Protection against vascular inflammation in endothelial cells represents a pivotal atheroprotective attribute of high-density lipoproteins (HDL). OBJECTIVE The present study sought to assess the predictive value of the HDL anti-inflammatory property for major adverse cardiovascular events (MACE). METHODS The anti-inflammatory property of HDL was evaluated by its ability to suppress vascular cell adhesion molecule-1 mRNA expression stimulated by tumor necrosis factor α in endothelial cells in a prospective study of patients with coronary artery disease from South China (n = 466, median follow-up of 2.3 years). The primary endpoint was MACE, encompassing nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death. RESULTS Within the study population (mean age 64.0 years, 77.9% male), 12.7% experienced recurrent MACE. After multivariable adjustment, higher HDL anti-inflammatory property was independently linked to lower residual cardiovascular risk (adjusted hazard ratio [aHR]: 0.96, 95% CI: 0.92-0.99; P = .022), with a linear inverse relationship (P for nonlinearity = .128). When divided into tertiles, patients with the highest HDL anti-inflammatory property showed significantly reduced MACE risk compared with the reference group in the multivariable-adjusted model (aHR: 0.48, 95% CI: 0.24-0.97; P = .040). Mediation analysis revealed that estimated glomerular filtration rate mediated 36.6% (P < .001) of the observed association. Moreover, subgroup analysis revealed a stronger protective effect in female patients (aHR: 0.73, 95% CI: 0.55-0.97). CONCLUSION Our findings indicate that better HDL anti-inflammatory function was linked to reduced recurrent MACE risk, independent of HDL cholesterol levels and statin treatment. Kidney function partially mediated this association. These findings underscore the prognostic relevance of HDL functional assessment in secondary cardiovascular prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoproteins, HDLCardiovascular DiseasesAnti-Inflammatory AgentsHumansFemaleMaleProspective StudiesMiddle AgedVascular Cell Adhesion Molecule-1AgedInflammationRisk Factors

Stichwörter der Autor:innen

AtherosclerosisHDL functionInflammationKidney functionLipoproteins

Substanzen

Lipoproteins, HDLVascular Cell Adhesion Molecule-1Anti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Jia, Wu, Xu, Xie, Liu, and Chen); Department of Guangdong Pr…

Förderung

  • Guangdong Provincial People&apos;s Hospital
  • National Natural Science Foundation of China
  • AstraZeneca

Zitieren

APA

Jia, C., Wu, W., Xu, X., Xie, Y., Liu, Y., & Chen, J. (2026). HDL anti-inflammatory capacity and residual cardiovascular risk: A prospective cohort study. Journal of Clinical Lipidology, 20(6), 1065-1077. https://doi.org/10.1016/j.jacl.2026.03.015

Vancouver

Jia C, Wu W, Xu X, Xie Y, Liu Y, Chen J. HDL anti-inflammatory capacity and residual cardiovascular risk: A prospective cohort study. Journal of Clinical Lipidology. 2026;20(6):1065-1077. doi:10.1016/j.jacl.2026.03.015

BibTeX
@article{Jia2026,
  author = {Jia, Congzhuo and Wu, Wanying and Xu, Xiayan and Xie, Yun and Liu, Yong and Chen, Jiyan},
  title = {HDL anti-inflammatory capacity and residual cardiovascular risk: A prospective cohort study},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  volume = {20},
  number = {6},
  pages = {1065--1077},
  doi = {10.1016/j.jacl.2026.03.015}
}
Kostenlos starten →